Prosecution Insights
Prosecution Insights
14 pending office actions • 10 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 17 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (7%) |
| §103 only | 4 (29%) |
| Double-patenting + other | 2 (14%) |
| No statute on record | 7 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 68.1% | +41.7% |
| DRISCOLL, MAUREEN VARINA | 1 | 68.0% | +35.3% |
| YAMASAKI, ROBERT J | 1 | 67.5% | +42.9% |
| STONEBRAKER, ALYSSA RAE | 1 | 54.4% | +52.8% |
| HUYNH, EMILY | 1 | 19.5% | +40.1% |
| WEN, SHARON X | 1 | 56.5% | +32.8% |
| CUNNINGCHEN, KATHLEEN MARY | 1 | 63.8% | +59.5% |
| AEDER, SEAN E | 1 | 56.9% | +19.6% |
| ZHU, JIANJIAN | 1 | 59.7% | +82.5% |
| KELLY, ROBERT M | 1 | 74.1% | +24.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | HUYNH, EMILY | 16d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18674418 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | YAMASAKI, ROBERT J | 117d overdue |
| 19011427 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | MOSELEY II, NELSON B | 92d overdue |
| 18256853 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | CUNNINGCHEN, KATHLEEN MARY | 1d overdue |
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | HUYNH, EMILY | 16d |
| 18262843 | ADJUVANT THERAPY FOR CANCER | WEN, SHARON X | 20d |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | KELLY, ROBERT M | 23d |
| 17997731 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | ZHU, JIANJIAN | 29d |
| 18247877 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | AEDER, SEAN E | 33d |
| Art Unit | Apps |
|---|---|
| 1642 | 3 |
| 1646 | 2 |
| 1638 | 2 |
| 1644 | 1 |
| 1657 | 1 |
| 3683 | 1 |
| 1641 | 1 |
| 1631 | 1 |
| 1633 | 1 |
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19011427 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | MOSELEY II, NELSON B | 1642 | §103 | Non-Final OA | 92d overdue | Pending | Jan 06, 2025 |
| 18886988 | TREATMENT WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH CTLA-4 AND PD-1 INHIBITORS | DRISCOLL, MAUREEN VARINA | 1644 | DPOther | Final Rejection | — | Pending | Sep 16, 2024 |
| 18674418 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES FROM LIQUID TUMORS AND THERAPEUTIC USES THEREOF | YAMASAKI, ROBERT J | 1657 | §103 | Non-Final OA | 117d overdue | Pending | May 24, 2024 |
| 18673083 | TREATMENT OF NSCLC PATIENTS REFRACTORY FOR ANTI-PD-1 ANTIBODY | STONEBRAKER, ALYSSA RAE | 1642 | Other | Final Rejection | 55d | Pending | May 23, 2024 |
| 18590860 | SYSTEMS AND METHODS FOR COORDINATING MANUFACTURING OF CELLS FOR PATIENT-SPECIFIC IMMUNOTHERAPY | HUYNH, EMILY | 3683 | §101 | Final Rejection | 16d | Pending | Feb 28, 2024 |
| 18262843 | ADJUVANT THERAPY FOR CANCER | WEN, SHARON X | 1641 | Other | Non-Final OA | 20d | Pending | Jul 25, 2023 |
| 18256853 | TREATMENT OF CANCERS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | CUNNINGCHEN, KATHLEEN MARY | 1646 | Other | Non-Final OA | 1d overdue | Pending | Jun 09, 2023 |
| 18247877 | TREATMENT OF NSCLC PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES | AEDER, SEAN E | 1642 | Other | Non-Final OA | 33d | Pending | Apr 04, 2023 |
| 17997731 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | ZHU, JIANJIAN | 1631 | Other | Non-Final OA | 29d | Pending | Nov 01, 2022 |
| 17829087 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | KELLY, ROBERT M | 1638 | Other | Non-Final OA | 23d | Pending | May 31, 2022 |
| 17267699 | Expansion of TILs from Cryopreserved Tumor Samples | O'NEILL, MARISOL ANN | 1633 | §103 | Final Rejection | 12d | Pending | Jan 10, 2022 |
| 17610671 | METHODS AND COMPOSITIONS FOR SELECTING TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | AMICK, THOMAS RUSSE | 1638 | DPOther | Non-Final OA | 70d | Pending | Nov 11, 2021 |
| 17420787 | SYSTEM AND METHODS FOR MONITORING ADOPTIVE CELL THERAPY CLONALITY AND PERSISTENCE | BEHARRY, ZANNA MARIA | 1632 | §103 | Final Rejection | 79d | Pending | Jul 06, 2021 |
| 17290705 | SELECTION OF IMPROVED TUMOR REACTIVE T-CELLS | REDDIG, PETER J | 1646 | Other | Non-Final OA | 259d overdue | Pending | Apr 30, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial